n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, October 17th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Investview, Inc. (INVU)

MarketWatch, InvestorsHub, Marketwired, Stockhouse, OTC Markets, Barchart, Stockflare, Investopedia, TradingView, and StockDeputy reported on Investview, Inc. (INVU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Investview, Inc. is a diversified financial technology enterprise. The Company operates mainly through its wholly- and majority-owned subsidiaries. Investview provides financial products and services to accredited investors, self-directed investors, and select financial institutions. The Company has its Wealth Generators wholly-owned subsidiary.

Incorporated in 2005, Investview is based in Salt Lake City, Utah. The Company previously went by the name Global Investor Services, Inc. It changed its corporate name to Investview, Inc. in March of 2012.

The Company’s Wealth Generators provides financial technology, education, and also research to individuals. Wealth Generators is not a brokerage firm or Registered Investment Advisor. It does not execute trades or take possession of clients' brokerage accounts. Its products undergo distribution by way of a direct sales model.

Wealth Generators’ products are provided to individuals on a monthly subscription basis. Wealth Generators is classified as a publisher of financial research and information and it is exempt from securities registration.

Via Wealth Generators, Investview provides education and technology designed to help individuals in navigating the financial markets. The Company’s services include tools and research, newsletter alerts, as well as live education rooms, which consist of instruction on the subjects of equities, options, FOREX, ETF’s, and binary options. Investview also offers education and technology applications to help individuals in debt reduction, enhanced savings, budgeting, and proper tax expense management.

Recently, Investview reported considerable increases in Net Revenue through its earlier acquisition of Wealth Generators. Before the acquisition of Wealth Generators, Investview reported Net Revenue of $131,465 and $353,926 in its statement of operations for the years ended March 31, 2017 and 2016, respectively. In those same periods, Wealth Generators reported Net Revenue of $12,872,947 and $5,557,461.

Ms. Annette Raynor, Investview’s Founder, Chief Operating Officer (COO) & Director, stated, "While we are still in the initial stages of establishing our post-acquisition operations, we believe this acquisition represents positive news for former shareholders and the ability for individuals who love our products to join us in our journey. We still have a way to go to reaching profitability, however the current public company structure and our continued growth in sales provides a future that is looking very bright."

Investview has completed its initial launch of Wealth Generator (WG) Startups that provides education and analysis of the crowdfunding marketplace. The initial webinar was delivered live by WG Startups Market Expert, Mr. Michael Markowski, on October 5, 2017 for Wealth Generators members.

Investview, Inc. (INVU), closed Tuesday's trading session at $0.051, down 28.07%, on 396,488 volume with 40 trades. The average volume for the last 60 days is 136,829 and the stock's 52-week low/high is $0.0016/$0.085.

El Capitan Precious Metals, Inc. (ECPN)

HotOTC, AllPennyStocks, PennyTrader Publisher, BullRally, MadPennyStocks, PennyStockVille, StockEgg, StockRich, TopPennyStockMovers, SmallCapVoice, PennyInvest, CoolPennyStocks, and OTCPicks reported on El Capitan Precious Metals, Inc. (ECPN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is a mining company listed on the OTC Markets Group’s OTCQB. It principally involves in the mining of precious metals and other minerals. The Company primarily holds interest in the El Capitan gold-silver property located close to Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals’ main asset is its wholly-owned subsidiary El Capitan, Ltd., an Arizona corporation. El Capitan Precious Metals is headquartered in Scottsdale, Arizona.

The El Capitan, Ltd. subsidiary holds the 100 percent equity interest in the El Capitan property. The Company’s main goal is the sale of the El Capitan property.

The El Capitan deposit has been known as a potential iron ore resource for many decades. The El Capitan deposit has a near-surface, pervasive nature. All of this takes place above the regional water table. This provides the potential for a low mining cost and a long life operation.

El Capitan Precious Metals owns 3,840 acres of mining property in Lincoln County. This includes 80 acres of patented and 3,760 acres of leased property. These include 188 mining claims. The El Capitan property covers 354 Bureau of Land Management (BLM) lode claims and four patented claims.

The Company has enhanced its relationship with Logistica US through an agreement under which El Capitan will provide to Logistica concentrated ore to their specifications at the mine site. Logistica will transport, process, and refine the precious metals concentrates to sell to precious metals buyers. The agreement is in addition to and complements the earlier announced agreement for the sale of iron ore for use in construction.

In August of this year, El Capitan Precious Metals confirmed that it received its initial payment on the sale of precious metals extracted from El Capitan ore in June 2017 from a domestic precious metals refinery. El Capitan then dispatched a second shipment of precious metal alloy bars to the refinery for processing and payment.

According to Mr. John F Stapleton, El Capitan Precious Metals Chairman and Chief Executive Officer, the first shipment was an important step in establishing protocols and procedures, which will be implemented in future, larger translations. The second shipment of precious metal alloy bars had a total weight of about 13.5 pounds, or approximately three times the weight of the first shipment.

El Capitan Precious Metals, Inc. (ECPN), closed Tuesday's trading session at $0.0436, up 3.81%, on 29,200 volume with 4 trades. The average volume for the last 60 days is 470,767 and the stock's 52-week low/high is $0.0399/$2.35.

CareView Communications, Inc. (CRVW)

Tiny Gems, Stock Stars, MonsterStocksPick, FeedBlitz, Real Pennies, PennyTrader Publisher, Wall Street Resources, BabyBulls, and MissionIR reported earlier on CareView Communications, Inc. (CRVW) and today we report on the Company, here at the QualityStocks Daily Newsletter.

CareView Communications, Inc. is an information technology (IT) provider to the healthcare industry. The Company provides the next generation of patient care by way of its leading-edge data and patient monitoring system. This system connects patients, families, and healthcare professionals (the CareView System®). CareView Communications has its corporate office in Lewisville, Texas.

The Company’s aim is to be the foremost provider of products and on-demand application services for the healthcare industry. This is through specializing in bedside video monitoring, archiving and patient care documentation systems and patient entertainment services. CareView’s proprietary, high-speed data network system may be deployed throughout a healthcare facility to provide the facility with recurring revenue and infrastructure for future applications.

CareView Communications’ dedication is to working with all types of hospitals, nursing homes, adult living centers, and selected outpatient care facilities domestically and worldwide. Its CareView System can help a hospital lessen sitter costs, reduce patient falls and injuries, manage patient flow, improve internal communications, and consolidate vendors.

The System uses an infrared camera in patient rooms to deliver real-time visual monitoring around the clock. CareView installs its equipment in healthcare facilities at no charge. It subsequently produces revenue from subscriptions to its set of products and services, which are priced as a bundled service.

The CareView System allows for close observation of high-risk patients from multiple locations. This is to reduce sitter costs and manage staffing resources more efficiently. Furthermore, the CareView Connect® mobile application provides patient monitoring and vital communication tools from an existing Wi-Fi Android or iOS device.

The CareView System is HIPAA-compliant (Health Insurance Portability and Accountability Act) and secure. The System does not record anything and it can include consent processes and privacy options. In addition, concerning hospital benefits, the CareView System enables patients to watch first-run movies and access high-speed internet. The result of this is increased patient satisfaction.

CareView Communications executed an agreement in 2017 with Dish Network, LLC, to become a Private Cable Operator (PCO). The agreement enables CareView Communications to provide television network services through Dish Network as part of its full set of products and services offered via its CareView System®.

In March of this year, CareView Communications announced the signing of another large member hospital group under its previously announced GPO agreement. The purchase agreement encompasses the 13 hospitals in the eastern division of the hospital group, which has an aggregated count of roughly 3,600 beds.

With this GPO agreement, exclusive members can buy all components of the Company's CareView System® video monitoring, archival and patient care documentation systems, and patient entertainment services. The GPO’s exclusive membership covers the greater than 1,600 acute care facilities and over 26,000 health facility locations.

CareView Communications, Inc. (CRVW), closed Tuesday's trading session at $0.0352, down 29.60%, on 162,300 volume with 22 trades. The average volume for the last 60 days is 49,913 and the stock's 52-week low/high is $0.03/$0.215.

Cell MedX Corp. (CMXC)

ResearchOTC, StockBlogs, Wall Street Beauties, StockRockandRoll, Daily Stock Motion, Penny Pick Insider, SMS Penny Picks, Penny Stocks VIP, SECFilings News, PennyStockLocks, FatCat Stocks, The Observer, and WINNINGOTC reported previously on Cell MedX Corp. (CMXC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cell MedX Corp concentrates on the discovery, development, and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, and high blood pressure. This is through developing technologies to help manage illness and related complications. The OTCQB-listed Company is at the forefront of creating devices, which treat chronic and acute conditions for clinical and self-management care. An early development stage bio-technology enterprise, Cell MedX is headquartered in Carson City, Nevada.

The Company manufactures and distributes medical devices powered by its proprietary, patented technology of low level current mainly for supporting chemical (pharmaceutical) treatments for diabetes. Cell MedX is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, called cellular medicine.

Also, via its wholly-owned subsidiary, Avyonce Cosmedics, Inc., the Company engages in the reselling and marketing of technology and equipment to the international wellness industry and providing continuing education to health care professionals.

Cell MedX’s goal is to release its initial lineup of commercial products. The Company will begin with its flagship product named ‘eBalance’, which works to improve the efficacy of the client’s existing medication regimes.

The eBalance brand includes consumer product development and professional versions for use within medical facilities. The design of them is to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance, and blood pressure.

The eBalance technology will form the foundation for a product line that will be available to assist in the management of diabetes mellitus (T1DM and T2DM) and its complications, as a professional clinic-based and a home use device. The eBalance Pro wellness device is an all-in-one, portable, and fully automated microcurrent delivery system.

Cell MedX has received an approval from the Ethics Review Board to commence its observational clinical trial in Canada. Cell MedX engaged Nutrasource Diagnostics, Inc. (NDI) to launch the observational clinical trial of its innovative and proprietary technology branded under the trade name eBalance. The objective of this Trial is to measure the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's baseline data and medical history.

Cell MedX has completed its registration process with the U.S. Food and Drug Administration (FDA) and initiated an application process to receive FDA clearance for use of its eBalance device as a Class II non-exempt device.

Fundamentally, the design of the eBalance technology developed by Cell MedX is to alleviate complications associated with certain medical conditions through reinvigorating the electrochemical system that naturally occurs in healthy cells. In the Company’s observational trials it has seen that by increasing cell activity, many of the conditions common in suffering individuals may stop and in some instances reverse. Pain is lessened, and non-healing wounds may heal. eBalance therapy may be applied on a scheduled basis or as needed.

Cell MedX Corp. (CMXC), closed Tuesday's trading session at $0.268369, down 2.54%, on 4,903 volume with 7 trades. The average volume for the last 60 days is 9,002 and the stock's 52-week low/high is $0.15/$0.475.

GelTech Solutions, Inc. (GLTC)

BullRally, InvestorPlace, CoolPennyStocks, HotOTC, SmallCapVoice, TheMicrocapNews, Investor Relations, OTC Picks, PennyTrader Publisher, Wise Alerts, CRWEFinance, and Stock Rich reported previously on GelTech Solutions, Inc. (GLTC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

GelTech Solutions, Inc. is a leading provider of unique, environmentally friendly, and cost-effective products. These products help government agencies, industry, agriculture, and the public reach goals, including water conservation and protecting lives, homes and property from fires. GelTech is an innovator in the use of environmentally-friendly polymers for fire suppression and protection. The Company is based in Jupiter, Florida.

GelTech Solutions has its FireIce Wildland Fire Division. It specializes in providing innovative fire chemicals and equipment, and also industry-leading training and support, to wildland fire agencies globally.

GelTech Solutions’ products include Fire Suppression, Industrial Absorbents, and Soil Amendments. FireIce® is a firefighting product. FireIce is in use at manifold fire departments throughout the nation as a supplement to their fire suppression equipment. FireIce has been approved by the United States Forest Service for use on the ground and from the air to suppress oncoming wildland fires.

FireIce® is a non-toxic dry polymer. When mixed with water it becomes a very effective and versatile gel used by wildland and municipal firefighting agencies as a suppressant to extinguish fires and as a fire retardant to protect assets and property. Additionally, FireIce can suppress specifically challenging manhole, tire, magnesium and other fires more than 10,000 degrees Fahrenheit. It can also suppress electrical fires of up to 50,000 volts.

GelTech Solutions is working with a number of industrial clients that are incorporating FireIce Shield® into their manufacturing process. This is to prevent fires and avoid expensive business interruptions while processing flammable materials.

GelTech Solution’s Soil2O Dust Control and Soil Cap are cost effective, polymer-based products. The construction and mining industries, farmers and local communities use these products to reduce airborne particulate matter with minimal environmental impact.

Soil2O Topical and Soil2O Granular are a line of moisture retention products. They are used in agriculture, commercial landscaping and by homeowners to improve crop, plant, and lawn health while lessening water usage by up to 50 percent.

The Company also has its GT-W14. This is an advanced absorbency technology. It is used by manufacturers, shippers, and auto maintenance facilities to control industrial fluid spills of all sizes, turning liquids into solid waste for easier and safer disposal.

This past June, GelTech Solutions announced that the FireIce Wildland Fire Division secured two new geographically dispersed western state firefighting agencies for the evaluation of FireIce products in airtankers. The agencies are running pilot programs that include the evaluation of new state-of-the-art tanker base loading equipment. Furthermore, the FireIce Wildland Fire Division is supporting the Oregon Department of Forestry for the third straight season, and Saskatchewan Northern Air Operations and Washington Department of Natural Resources for the second season.

GelTech Solutions has launched its FireIce Lithium Battery Active Suppression Kit. It automatically detects elevated temperatures releasing FireIce ST, a special blend of FireIce, to the affected battery module, to cool and suppress the batteries and prevent the system from reaching runaway that could cause an explosion. The design of the kit is to deliver FireIce ST product only to the battery compartment where it is required, leaving other compartments untouched.

GelTech Solutions, Inc. (GLTC), closed Tuesday's trading session at $0.1897, up 11.75%, on 400 volume with 2 trades. The average volume for the last 60 days is 22,073 and the stock's 52-week low/high is $0.16/$0.65.

Butler National Corp. (BUKS)

Marketbeat, Zacks, MarketWatch, and FeedBlitz reported earlier on Butler National Corp. (BUKS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Butler National Corp. is a foremost manufacturer and provider of support systems for commercial and military aircraft. In addition, the Company is a recognized provider of management services in varied business groups. These include the gaming industry. Butler operates in the Aerospace/Defense Products & Services industry in the Industrial Goods sector. It is a leader in the increasing international market for aircraft structural modification, maintenance, repair and overhaul (MRO). Butler National is headquartered in Olathe, Kansas.

The Company established in 1968 via the merger of an aviation research firm owned by the Butler family and National Connector Corporation. Butler National combined resources of the two companies to develop one of the first commercial Area Navigation Systems (RNAV) used for airplane navigation.

Butler’s subsidiaries include Avcon Industries, Inc.; Butler Avionics, Inc.; BCS Design, Inc.; Boot Hill Casino & Resort; The Stables Casino; and Butler National-Tempe. Avcon Industries provides aircraft owners and operators with products and services designed to satisfy special mission requirements, or enhance the utility of business jets and turboprops.

Butler National’s Aerospace segment focuses on the manufacturing of support systems for "Classic" commercial and military aircraft. This includes the Butler National TSD for the Boeing 737 and 747 Classic aircraft. This segment also focuses on switching equipment for Boeing McDonnell Douglas Aircraft, weapon control systems for Boeing Helicopter, and performance enhancement structural modifications for Learjet, Cessna, Dassault, and Beechcraft business aircraft.

Boot Hill Casino & Resort is in Dodge City, Kansas. It is home to the first state owned and operated casino gaming in Kansas. The Stables Casino is a Class III gaming establishment in Miami, Oklahoma. It is owned by the Miami Tribe and the Modoc Tribe. Butler National-Tempe operates in the Defense Contracting & Electronics industry.

The Company’s Management Services segment includes temporary employee services, gaming services, as well as administrative management services. Butler Avionics’ services include new installations and retrofits, to avionics, autopilot, instruments, and radar troubleshooting and repair. BCS Design is a full-service architectural firm.

Butler National announced in April 2017 Federal Aviation Administration (FAA) Supplemental Type Certificate issuance and Parts Manufacturing Approval of a new vertical accelerometer for Learjet airplanes. The Company designed, manufactured, and obtained FAA Supplemental Type Certificate (STC) approval of a replacement vertical accelerometer for use by the autopilot on the applicable Learjet Model 31/35/35A/36/36A/C-21A and 55 Series airplanes.

Last month, Butler National announced its financial results for Q1 fiscal 2018 ended July 31, 2017. Mr. Clark D. Stewart, Butler National President, said, “The fiscal quarter-ended July 31, 2017 was a positive beginning to fiscal year 2018. Revenue increased 2 percent to $11.6 million in the three months ended July 31, 2017, as compared to $11.4 million in the three months ended July 31, 2016… First quarter fiscal 2018 resulted in a net income of $238,000 compared to a net income of $224,000 in the first quarter fiscal 2017.”

Butler National Corp. (BUKS), closed Tuesday's trading session at $0.32, up 3.23%, on 25,285 volume with 8 trades. The average volume for the last 60 days is 39,948 and the stock's 52-week low/high is $0.1551/$0.4799.

Astea International, Inc. (ATEA)

Zacks, OTC Markets, MarketWatch, InvestorsHub, Stocktwits, Stockhouse, Business Insider, and The Street reported on Astea International, Inc. (ATEA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Astea International, Inc. is a worldwide leader in field service and mobile workforce management. The Company’s solutions unify processes, people, parts, and information to focus the whole organization on the creation of sustainable value in highly competitive, international markets. Astea provides integrated solutions to help in maximizing efficiencies, improve revenues, and enhance customer satisfaction.

OTCQB-listed, Astea International is headquartered in Horsham, Pennsylvania. The Company was recognized by Frost & Sullivan with the 2017 Customer Value Leadership Award for its industry-leading mobile workforce management solution.

The Company is an international provider of end-to-end service management software solutions. These solutions offer all the foundations of service lifecycle management. These include customer management, depot repair, service management, asset management, warranty management, forward and reverse logistics management, and mobile workforce management and optimization.

Astea International’s solutions allow companies to streamline and automate business processes; condense the contract-to-cash cycle; collapse non-value added workflows, and enhance resource utilization and decrease downtime. Its solutions also enable companies to Identify incremental sales opportunities and improve revenue recovery and coordinate the efforts of sales, marketing, and service organizations. Furthermore, its solutions allow companies to improve compliance with Service Level Agreements (SLAs), contracts, and warranties, and also harmonize every customer touch point for increased customer satisfaction.

Astea International has expertise in service management, distribution, logistics, and system applications. These can help an organization streamline business processes, incorporate services best practices, decrease costs, and realize the highest returns from their technology investment. The main elements of its professional services are impact assessment, consulting services, and training & support.

Astea International provides on-premise and cloud delivery models. This permits every company to select the right one that aligns with their strategy and Information Technology (IT) ecosystem.

The Company has licensed applications to enterprises globally in a broad range of sectors. These include Medical Device & Diagnostics; IT/High Tech Equipment; Imaging/Copiers/Office Equipment; Industrial Equipment; Scientific & Technical Instruments; HVAC; Process Controls & Instrumentation; and Construction. In addition, these include Point of Sale Equipment; Telecommunications; Food Service Equipment; Fire & Security; Professional/IT Services; Property/Facilities Management Services; as well as Gaming/Leisure Equipment.

Astea International, via its Japanese subsidiary, has partnered with Kobelco Systems Corporation. This is to enable wide-ranging Internet of Things (IoT) and Artificial Intelligence (AI) capabilities on its field service management platform, Astea Alliance™.

Kobelco Systems' IoT infrastructure platform and AI analytical service are now completely integrated into the Astea Alliance platform to optimize the maintenance activities of original equipment manufacturers (OEMs), improving overall productivity for assembly lines, plants, as well as supply chains. Currently, Astea International and Kobelco Systems are working to further develop the IoT- and AI-enabled platform to include augmented reality, remote maintenance and artificial intelligence voice and character recognition.

Astea International, Inc. (ATEA), closed Tuesday's trading session at $2.37, even for the day, on 10,000 volume with 1 trade. The average volume for the last 60 days is 13,597 and the stock's 52-week low/high is $0.0001/$0.62.

graphic

The QualityStocks
Company Corner

graphic
graphic

RJD Green Inc. (RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (RJDG). Today, RJD Green Inc. closed trading at $0.00865, off by 0.57%, on 580,822 volume with 15 trades. The stock’s average daily volume over the past 60 days is 1,902,879, and its 52-week low/high is $0.0024/$0.029.

RJD Green, Inc. (RJDG), a holding company focused in green environmental services, healthcare technology and services, and manufacturing / distribution of construction and industrial product, has announced changes in its board of directors. The Company accepted the resignation of Rex Washburn as Director due to compelling health issues. Mr. Washburn will continue to serve in an advisory role to the Board.

RJD Green Inc. (RJDG) is a holding company with a focus on acquiring and managing assets and companies in three divisions. These initial high-growth enterprise opportunities offer diversity in separate recession resistant markets. The division holdings include:

  • RJD Green Healthcare Services – provides services to reduce cost and enhance management and operational capabilities in the healthcare sector.
  • Earthlinc Environmental Services – provides green environmental services and technologies.
  • Silex Holdings – acquires specialty construction and industrial manufacturing assets.

RJD Green Healthcare Services, through its wholly owned subsidiary IOSOFT Inc., provides proprietary software and IT support for medical billing, healthcare claims adjudication, and electronic payments between healthcare payers and providers. IOSOFT's unique payment technologies and services or software can be integrated with existing systems of healthcare payers such as Blue Cross, Aetna, CIGNA and others. IOSOFT provides targeted offerings for healthcare providers, provider networks, physicians and hospitals, and clearinghouse companies.

Earthlinc Environmental Solutions was formed to bring forward green-applied technologies and offer environmental services with a focus on North America. The division's first acquisition, Animal Waste Management, is launching operations of a patented, fully developed technology for processing waste produced on commercial poultry and hog farms. Development of this technology was supported by the University of Arkansas and the Missouri Department of Natural Resources. This important technology improves the farm's productivity and is competitively priced with the current expense of handling waste removal at these sites.

The company's third division – Silex Holdings Inc. – was formed to acquire and manage high-growth assets and business enterprises in the industrial and construction specialty services sectors. With its first acquisition of Silex Interiors, a manufacturer, distributor and installer of counter tops, cabinets and related kitchen and bath products, the division is poised to expand into major national markets through internal expansion, acquisition and franchising. The company is modeled to operate a minimum of four corporately owned locations with 12 to 18 franchise locations nationwide.

RJD Green seeks to participate as owners, partners or in joint ventures in a wide range of business enterprises. The company's goal of creating a successful, enjoyable business enterprise for its company team and staff, along with its business partners and investors, is paired with the goal of maximizing the business potential of the enterprise by enhancing profits and the quality of the company. Disclaimer

RJD Green Inc. Company Blog

RJD Green Inc. News:

RJD Green Inc. Appoints Director

RJD Green Inc. Subsidiary, IOSOFT, Discusses Contracts Procured and Revenue Expectations

RJD Green Inc. Announces The Silex Holdings Division Contract Awarded as Preferred Vendor

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.0263, up 1.94%, on 1,590,092 volume with 116 trades. The stock’s average daily volume over the past 60 days is 4,869,171 and its 52-week low/high is $0.0111/$0.1985.

Marijuana Company of America Inc. (MCOA), an innovative hemp and cannabis corporation with diverse operations and joint ventures in the legal hemp and cannabis industry, announced today that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW"). MCOA's Chief Executive Officer, Donald Steinberg, commented: "We are pleased to utilize NetworkNewsWire's messaging and branding strategies to communicate to the investment community Marijuana Company of America's position in the cannabis industry. We are at a crossroads of global legalization of our industry. The world has a massive need for cannabis and hemp products and services. This process of countries shifting to a legal cannabis and hemp structure is something that will occur only once in the history of a country, and we are proud to be a frontrunner in the industry."

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Marijuana Company of America Engages NetworkNewsWire for Corporate Communications Solution

Marijuana Company of America and Global Hemp Group to Form Joint Venture With Space Cowboys' Colorado Farm

Marijuana Company of America, Inc. (MCOA) is “One to Watch”

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.06, up 0.84%, on 3,023,075 volume with 181 trades. The stock’s average daily volume over the past 60 days is 3,931,705, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc. (POTN) announced today that its wholly owned subsidiary, Diamond CBD, Inc., achieved $3,224,017 in combined sales for July and August; ($1,459,137 and $1,764,880 respectively), discovering results equivalent to over 60% of revenues totaling $5,077,625 for the first six months of the year, raising expectation for another record breaking quarter.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding, Inc. Projects Third Quarter Revenues Will Top First Six Months Results, Based on Record Sales Volume for July and August

Exceeding $1,750,000.00 in Revenues for August, PotNetwork Holding, Inc.’s Diamond CBD Hits Highest Revenues Recorded to Date

PotNetwork Holding Inc. Strengthens Advisory Board with the Appointment of Distinguished Medical Marijuana Certified Physician

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.064, off by 5.88%, on 40,073 volume with 9 trades. The stock’s average daily volume over the past 60 days is 115,151 and its 52-week low/high is $0.003/$0.33.

Skinvisible, Inc. (SKVI), a research and development company whose patented Invisicare® delivery technology can be used to revitalize or create new medical or skincare products, including those offered within the medicinal and recreational cannabis market, announces that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW").

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible, Inc. (SKVI) Engages NetworkNewsWire for Corporate Communications Solutions

Skinvisible, Inc. (SKVI) is “One to Watch”

Skinvisible and Canopy Growth Enter License Agreement

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0586, even for the day, on 3,375,875 volume with 203 trades. The stock’s average daily volume over the past 60 days is 19,299,743, and its 52-week low/high is $0.0075/$0.415.

Singlepoint, Inc. (SING) today announces its acquisition of Denver-based group, JAG, and offers an update on several corporate initiatives. Through July 2017, JAG recorded $600,000 in revenue with approximately 26% gross margins, following full-year 2016 revenue of $700,000. JAG has achieved year-over-year growth since starting its operations in 2014, and moving forward will provide SinglePoint consistent, predictable monthly revenue. Per the agreement terms, SinglePoint will acquire fifty-one percent (51%) of JAG in a combination of cash and stock, which will allow the Company to recognize all revenues.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Completes Acquisition of Profitable Denver Colorado-Based Company

CannabisNewsWire Announces Publication on Public Companies Offering Secondary Services to the Cannabis Industry

SinglePoint Receives $1.2 Million in Funding With Option to Raise a Total of $4 Million

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.864, off by 5.68%, on 673,065 volume with 369 trades. The stock’s average daily volume over the past 60 days is 225,917 and its 52-week low/high is $0.6171/$1.25.

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) today announces that Ken Clement, founder and Executive Chair, has decided to step down from his position as Executive Chair, but will continue as a member of the Company’s board of directors (the “Board”). As a result, the Board has unanimously appointed Paul Lucas as Chair of the Board. Mr. Lucas is an independent director of the Company and Chair of the Nominating and Corporate Governance Committee.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

SinglePoint Completes Acquisition of Profitable Denver Colorado-Based Company

CannabisNewsWire Announces Publication on Public Companies Offering Secondary Services to the Cannabis Industry

SinglePoint Receives $1.2 Million in Funding With Option to Raise a Total of $4 Million

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.32991, off by 5.74%, on 547,953 volume with 232 trades. The stock’s average daily volume over the past 60 days is 460,228, and its 52-week low/high is $0.09/$0.72.

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today additional pre-clinical results in the development of INM-405 for the treatment of pain. In recent pre-clinical testing, InMed employed several methods to verify the effects of individual, non-THC (tetrahydrocannabinol, the primary psychoactive ingredient in cannabis) cannabinoids, as well as a matrix of cannabinoid combinations, delivered to treat peripheral pain:

  • in vivo animal models of pain to measure the pain tolerance;
  • in vivo electrophysiology recordings to measure the blockage of pain signal transmission in the peripheral nerve fibres; and
  • in vivo behavioral studies to verify the central nervous system (CNS) related side effects.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Updates Pain Program

InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board

InMed Pharmaceuticals Files Provisional Patent for Pain Program

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(NEOT) +231.15%

2.

MarketBeat
(QRMLF) +125.00%

3.

QualityStocks
(TAPM) +80.36%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251